ac

AC Immune

ACIU
NASDAQ
$2.70

Does AC Immune have high-quality management?

Founder‑CEO Dr. Andrea Pfeifer has historically secured multiple large‑pharma deals and owns meaningful equity; however, she announced plans to retire at the upcoming 2026 AGM, with the board chair to serve as interim CEO during the search. Governance includes experienced industry figures, though the transition adds uncertainty before pivotal data.

Insider and major holders include BVF and dievini Hopp BioTech. On balance, the track record on partnering is strong, but leadership transition ahead of key readouts tempers our score.

Read the full report on AC Immune and explore the other sections

Overview
Overview of AC Immune
Moat
Does AC Immune have a strong competitive moat?
Pricing Power
Does AC Immune have pricing power in its industry?
Predictability
How predictable is AC Immune's business?
Financial Strength
Is AC Immune financially strong?
Capital Allocation
How effective is AC Immune's capital allocation strategy?
Management
Does AC Immune have high-quality management?
Fair Value
What is the fair value of AC Immune stock?